Investigational Drug Information for EIDD-2801

What is the development status for investigational drug EIDD-2801?

EIDD-2801 is an investigational drug.

There have been 6 clinical trials for EIDD-2801. The most recent clinical trial was a Phase 2 trial, which was initiated on June 16^th 2020.

The most common disease conditions in clinical trials are COVID-19, Coronavirus Infections, and Renal Insufficiency. The leading clinical trial sponsors are Ridgeback Biotherapeutics, LP, Merck Sharp & Dohme LLC, and Lancaster University.

There are one hundred and twelve US patents protecting this investigational drug and forty-four international patents.

Summary for EIDD-2801

US Patents	112
International Patents	44
US Patent Applications	593
WIPO Patent Applications	543
Japanese Patent Applications	12
Clinical Trial Progress	Phase 2 (2020-06-16)
Vendors	60

Recent Clinical Trials for EIDD-2801

Title	Sponsor	Phase
A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)	Merck Sharp & Dohme LLC	Phase 1
A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)	Merck Sharp & Dohme LLC	Phase 1
AGILE (Early Phase Platform Trial for COVID-19)	Lancaster University	Phase 1/Phase 2

See all EIDD-2801 clinical trials

Clinical Trial Summary for EIDD-2801

Top disease conditions for EIDD-2801

Top clinical trial sponsors for EIDD-2801

See all EIDD-2801 clinical trials

US Patents for EIDD-2801

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
EIDD-2801
EIDD-2801		Compositions and methods for treating SARS-CoV-2 infections	Morehouse School of Medicine Inc
EIDD-2801
EIDD-2801		Methods and compositions for treating coronavirus infections	Morehouse School of Medicine Inc
EIDD-2801		Inhibitors of cysteine proteases and methods of use thereof	Pardes Biosciences Inc
EIDD-2801		Process for molnupiravir	Optimus Drugs Pvt Ltd

International Patents for EIDD-2801

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
EIDD-2801	Argentina	AR123111	2040-09-03
EIDD-2801	Australia	AU2021266232	2040-09-03
EIDD-2801	Australia	AU2022202158	2040-09-03
EIDD-2801	Australia	AU2022221493	2040-09-03
EIDD-2801	Brazil	BR112021022419	2040-09-03
EIDD-2801	Canada	CA3137824	2040-09-03

Development Update and Market Projection for EIDD-2801

Last updated: February 16, 2026

Overview

EIDD-2801, also known as molnupiravir, is an oral antiviral developed by Merck (MSD) with potential applications against COVID-19. As of Q1 2023, the drug is in late-stage clinical development, with the goal of providing outpatient treatment for mild-to-moderate COVID-19 cases. It has completed phase 2 and phase 3 trials, with data supporting its efficacy and safety profile. The market for oral antivirals targeting COVID-19 remains competitive, with EIDD-2801 positioned to address unmet needs in outpatient management.

---

Development Status

Clinical Trials and Regulatory Progress

• Phase 3 Trial Results: Published preliminary data indicate that molnupiravir reduces hospitalization or death in at-risk, non-hospitalized COVID-19 patients by approximately 50% compared to placebo. The trial, MOVe-OUT, enrolled over 1,400 participants across multiple countries.

• Regulatory Submissions: Merck filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in November 2022. The FDA granted EUA in December 2022, conditional on further data review.

• Global Approvals: Regulatory agencies in the UK (MHRA), Canada (Health Canada), and Australia (Therapeutic Goods Administration) have approved molnupiravir for emergency or conditional use. Full approval status varies by jurisdiction.

• Manufacturing and Distribution: Merck has secured manufacturing capacity exceeding 10 million treatment courses for 2023, with plans to ramp up based on demand and approval status.

Patent and Licensing Landscape

• Merck holds patents protecting molnupiravir through at least 2030, covering formulations and methods of use. Additional licensing agreements aim to support global access in low- and middle-income countries.

---

Market Dynamics and Projections

Current Market Context

• Competition: Pfizer's Paxlovid (nirmatrelvir/ritonavir) dominates the oral antiviral market with over 50% global market share as of early 2023. Other candidates, including remdesivir (intravenous) and emerging oral therapies, vie for market space.

• Demand Drivers: Rising COVID-19 caseloads and the shift toward outpatient treatment favor oral antivirals. Variants causing breakthrough infections in vaccinated populations sustain demand for additional therapeutic options.

• Pricing and Reimbursement: In the U.S., Merck's molnupiravir is priced approximately $700 per treatment course. Cost-effectiveness analyses favor oral antivirals in reducing hospitalizations, supporting favorable reimbursement policies.

Market Size Estimates

• Global Market Volume: The outpatient antiviral market for COVID-19 is estimated to reach $3-5 billion in 2023, reflecting continued infections and treatment needs.

• Projected Sales Trajectory:

Year	Estimated Market Share	Projected Revenue (USD Billion)	Notes
2023	10-15%	0.2-0.75	Initial adoption, pending full approval, sales ramp-up
2024	20-25%	0.6-1.25	Increased adoption, expanded approvals
2025	25-35%	0.9-1.75	Market penetration, competition persists

• Key Factors Influencing Market Adoption: Regulatory decisions, real-world efficacy data, pricing strategies, and competition from Paxlovid and emerging therapies.

Long-term Outlook (2025 and Beyond)

• The market could stabilize around $2 billion annually, especially if COVID-19 transitions into endemicity with annual surges. Structural advantages over competitors, such as ease of manufacturing or superior safety, can enhance market share.

• The durability of molnupiravir depends on emerging variants, resistance development, and comparative efficacy data from ongoing studies.

---

Regulatory and Commercial Risks

• Efficacy and Safety Data: Further data is required to confirm efficacy across variants and to delineate safety in broader populations.

• Global Access and Pricing: Differential pricing and licensing may influence market uptake, especially in low-income markets reliant on licensing agreements.

• Competitor Innovation: Superior products or novel delivery mechanisms from competitors could erode market share.

---

Key Takeaways

• EIDD-2801 (molnupiravir) is in late-stage clinical development, with regulatory approval in multiple regions. Its efficacy in reducing hospitalization in outpatient COVID-19 patients has been demonstrated in phase 3 trials.

• Market projections suggest a gradual accumulation of sales, reaching approximately $1-2 billion globally by 2025, making it a significant component of COVID-19 outpatient therapy.

• Competitive landscape centers around Pfizer's Paxlovid, which currently holds dominant market share, but molnupiravir offers advantages in manufacturing and oral administration.

• Risks include evolving viral variants, safety considerations, pricing policies, and the competitive pipeline.

---

FAQs

1. What is the current regulatory status of molnupiravir?

   • It has received Emergency Use Authorization or conditional approval in several markets, including the U.S., UK, and Canada. Full approval processes are ongoing in other jurisdictions.

2. How does molnupiravir compare to Paxlovid in efficacy?

   • Phase 3 data show molnupiravir reduces hospitalization or death by around 50%, while Paxlovid reports reductions exceeding 85%. However, direct comparisons are limited due to differing trial designs.

3. What are the dosing specifics for molnupiravir?

   • The approved regimen is 800 mg (four 200 mg capsules) taken twice daily for five days.

4. Are there concerns regarding resistance or safety?

   • Long-term safety data are limited, but current studies report acceptable safety profiles. Resistance development remains a theoretical concern requiring ongoing monitoring.

5. What is the supply outlook for 2023?

   • Merck has manufacturing capacity exceeding 10 million courses for 2023, with plans for expansion depending on demand and regulatory approvals.

---

Citations

[1] Merck press releases and regulatory filings.
[2] Clinical trial data published in The New England Journal of Medicine.
[3] Market research reports from IQVIA and GlobalData.